Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10773/37973 |
Resumo: | Background: Cervical cancer is a major concern to women’s health, being the fourth most common cancer world‑ wide. A great percentage of these cancer is consequence of an HPV infection, namely from specifc genotypes such as 16/18. Portuguese screening program subjects women to a refex cytology triage every 5 years. Aptima® HPV is a screening test which presents better specifcity than other tests which are used in Portugal (Hybrid Capture® 2 and Cobas® 4800) and still have a comparable sensitivity. The present study aims to estimate the number of diagnostic tests and costs that are avoided using Aptima® HPV compared to the use of two other tests, Hybrid Capture® 2 and Cobas® 4800, within the cervical cancer screening programme in Portugal. Methods: A model, consisting of a decision-tree, was developed to represent the full Portuguese screening program for cervical cancer. This model is used to compare the costs resulting from using Aptima® HPV test versus the other tests used in Portugal, during 2 years. Other outcomes such as the number of additional tests and exams were also computed. This comparison considers the performance of each test (sensitivity and specifcity) and assumes an equal price for every test compared. Results: Cost savings resulting from the use of Aptima® HPV are estimated at approximately €382 million versus Hybrid Capture® 2 and €2.8 million versus Cobas® 4800. Moreover, Aptima® HPV prevents 265,443 and 269,856 addi‑ tional tests and exams when compared with Hybrid Capture® 2 and Cobas® 4800. Conclusions: The use of Aptima® HPV resulted in lower costs as well as less additional test and exams. These values result from the greater specifcity of Aptima® HPV, which signals less false positive cases and consequently avoids car‑ rying out additional tests. |
id |
RCAP_70e6e357f632150b40bb1d9338d345b7 |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/37973 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysisEarly detection of cancerPapillomavirus infectionsCervical cancerCosts and cost analysisBackground: Cervical cancer is a major concern to women’s health, being the fourth most common cancer world‑ wide. A great percentage of these cancer is consequence of an HPV infection, namely from specifc genotypes such as 16/18. Portuguese screening program subjects women to a refex cytology triage every 5 years. Aptima® HPV is a screening test which presents better specifcity than other tests which are used in Portugal (Hybrid Capture® 2 and Cobas® 4800) and still have a comparable sensitivity. The present study aims to estimate the number of diagnostic tests and costs that are avoided using Aptima® HPV compared to the use of two other tests, Hybrid Capture® 2 and Cobas® 4800, within the cervical cancer screening programme in Portugal. Methods: A model, consisting of a decision-tree, was developed to represent the full Portuguese screening program for cervical cancer. This model is used to compare the costs resulting from using Aptima® HPV test versus the other tests used in Portugal, during 2 years. Other outcomes such as the number of additional tests and exams were also computed. This comparison considers the performance of each test (sensitivity and specifcity) and assumes an equal price for every test compared. Results: Cost savings resulting from the use of Aptima® HPV are estimated at approximately €382 million versus Hybrid Capture® 2 and €2.8 million versus Cobas® 4800. Moreover, Aptima® HPV prevents 265,443 and 269,856 addi‑ tional tests and exams when compared with Hybrid Capture® 2 and Cobas® 4800. Conclusions: The use of Aptima® HPV resulted in lower costs as well as less additional test and exams. These values result from the greater specifcity of Aptima® HPV, which signals less false positive cases and consequently avoids car‑ rying out additional tests.BMC2023-06-09T08:33:14Z2023-03-09T00:00:00Z2023-03-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10773/37973eng10.1186/s12905-023-02219-0Figueiredo, DanielRibeiro, InêsPenedones, AnaMendes, DiogoAlves, CarlosBatel-Marques, FranciscoSilva, Daniel Pereira dainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:11:57Zoai:ria.ua.pt:10773/37973Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:07:54.929277Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
title |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
spellingShingle |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis Figueiredo, Daniel Early detection of cancer Papillomavirus infections Cervical cancer Costs and cost analysis |
title_short |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
title_full |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
title_fullStr |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
title_full_unstemmed |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
title_sort |
Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
author |
Figueiredo, Daniel |
author_facet |
Figueiredo, Daniel Ribeiro, Inês Penedones, Ana Mendes, Diogo Alves, Carlos Batel-Marques, Francisco Silva, Daniel Pereira da |
author_role |
author |
author2 |
Ribeiro, Inês Penedones, Ana Mendes, Diogo Alves, Carlos Batel-Marques, Francisco Silva, Daniel Pereira da |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Figueiredo, Daniel Ribeiro, Inês Penedones, Ana Mendes, Diogo Alves, Carlos Batel-Marques, Francisco Silva, Daniel Pereira da |
dc.subject.por.fl_str_mv |
Early detection of cancer Papillomavirus infections Cervical cancer Costs and cost analysis |
topic |
Early detection of cancer Papillomavirus infections Cervical cancer Costs and cost analysis |
description |
Background: Cervical cancer is a major concern to women’s health, being the fourth most common cancer world‑ wide. A great percentage of these cancer is consequence of an HPV infection, namely from specifc genotypes such as 16/18. Portuguese screening program subjects women to a refex cytology triage every 5 years. Aptima® HPV is a screening test which presents better specifcity than other tests which are used in Portugal (Hybrid Capture® 2 and Cobas® 4800) and still have a comparable sensitivity. The present study aims to estimate the number of diagnostic tests and costs that are avoided using Aptima® HPV compared to the use of two other tests, Hybrid Capture® 2 and Cobas® 4800, within the cervical cancer screening programme in Portugal. Methods: A model, consisting of a decision-tree, was developed to represent the full Portuguese screening program for cervical cancer. This model is used to compare the costs resulting from using Aptima® HPV test versus the other tests used in Portugal, during 2 years. Other outcomes such as the number of additional tests and exams were also computed. This comparison considers the performance of each test (sensitivity and specifcity) and assumes an equal price for every test compared. Results: Cost savings resulting from the use of Aptima® HPV are estimated at approximately €382 million versus Hybrid Capture® 2 and €2.8 million versus Cobas® 4800. Moreover, Aptima® HPV prevents 265,443 and 269,856 addi‑ tional tests and exams when compared with Hybrid Capture® 2 and Cobas® 4800. Conclusions: The use of Aptima® HPV resulted in lower costs as well as less additional test and exams. These values result from the greater specifcity of Aptima® HPV, which signals less false positive cases and consequently avoids car‑ rying out additional tests. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06-09T08:33:14Z 2023-03-09T00:00:00Z 2023-03-09 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/37973 |
url |
http://hdl.handle.net/10773/37973 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1186/s12905-023-02219-0 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
BMC |
publisher.none.fl_str_mv |
BMC |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137733171478528 |